Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K$_1$) in severe acute liver disease failure

**Running head:** Vitamin K$_1$ in acute liver failure

STEPHEN P. PEREIRA$^{1,2}$, DAVID ROWBOTHAM$^1$, SARAH FITT$^1$, MARTIN J SHEARER$^3$, JULIA WENDON$^1$, ROGER WILLIAMS$^{1,2}$.

$^1$Institute of Liver Studies, King’s College Hospital, $^2$Institute of Hepatology, University College London, and $^3$Vitamin K Research & Diagnostic Units, The Haemophilia Reference Centre, St Thomas’ Hospital, London, UK.

**Abbreviations used in this paper:**

ALF, acute liver failure
AST, aspartate aminotransferase

HPLC, high-performance liquid chromatography

INR, international normalised ratio

MM K$_1$, mixed-micellar vitamin K$_1$

PIVKA, $P$roteins $I$nduced by $V$itamin $K$ $A$bsence or $A$ntagonism

PIVKA-II, undercarboxylated prothrombin (factor II)

---

*Address correspondence and requests for reprints to:*

Dr Steve Pereira

Institute of Hepatology

University College London Medical School

69-75 Chenies Mews

London WC1E 6HX

Tel: +44 20 7679 6510

Fax: +44 20 7380 0405

E-mail: stephen.pereira@ucl.ac.uk

---

*Abstract word count (excluding section titles): 200*

*Main text word count: 3,188 - 132 (Table 1) - 57 (Figure legends) = 2,999*
ABSTRACT

**Background & Aims:** In patients with severe acute liver dysfunction, i.v. phylloquinone (vitamin K₁) is often may be given to exclude vitamin K deficiency, rather than impaired hepatic synthesis of coagulation factors alone, as the cause of the coagulopathy. However, there have been no studies of the pharmacokinetics or efficacy of i.v. or oral K₁ in such patients. **Methods:** 49 adults with severe acute liver disease were randomised double-blind to a single 10 mg dose of i.v. or oral mixed-micellar K₁, or placebo. Serum levels of phylloquinone and undercarboxylated prothrombin (PIVKA-II) were assessed before and after treatment. **Results:** At admission, 13 patients (27%) had either low serum K₁ levels or elevated PIVKA-II concentrations, indicative of subclinical vitamin K deficiency. In the 16 patients who received i.v. K₁, there was one (6%) treatment failure (K₁ rise < 10 ng/ml above baseline), compared with 12 of the 15 (80%) who received oral K₁ (p<0.0001). One patient in the placebo group developed overt vitamin K deficiency. **Conclusions:** A minority of patients with severe acute liver dysfunction have subclinical vitamin K deficiency at the time of presentation, which is corrected by a single dose of i.v. K₁. The intestinal absorption of mixed-micellar K₁ is unreliable in adults with severe acute liver dysfunction.

INTRODUCTION

Vitamin K is an essential cofactor for the production in the liver of biologically active forms of the coagulation factors II (prothrombin), VII, IX, and X. Its role is to promote the conversion of certain glutamic acid residues in the protein precursors to γ-carboxyglutamic acid (Gla). The Gla-residues of these coagulation factors provide
an efficient chelating site for calcium ions and are essential for protein-membrane interaction and effective haemostatic function. When $\gamma$-carboxylation is impaired because of deficiency or antagonism of vitamin K, inert precursors of vitamin K-dependent proteins — known as Proteins Induced by Vitamin K Absence or Antagonism (PIVKA) — are synthesised in the liver and released into the blood. In the case of prothrombin, specific and sensitive immunoaassays have been developed which can detect small decreases in the Gla content of prothrombin before any changes occur in conventional coagulation tests such as the International Normalised Ratio (INR).

The major dietary form of vitamin K is phylloquinone (vitamin K$_1$; K$_1$), which is derived predominantly from green leafy vegetables. Its intestinal absorption involves the intraluminal solubilisation of vitamin K into mixed micelles composed of bile salts and the products of pancreatic lipolysis. This absorption is known to be impaired in patients with extrahepatic biliary obstruction and severe pancreatic insufficiency, but there are no data in patients with liver disease. Although impaired hepatic synthesis is almost certainly the dominant factor in the development of the usually severe coagulopathy seen in patients with acute liver failure (ALF), such patients may also have multiple risk factors for vitamin K deficiency, including poor oral intake, severe cholestasis and treatment with broad spectrum antibiotics — which inhibit production of menaquinones (vitamin K$_2$) by certain intestinal bacteria and their subsequent ileal absorption. Consequently, it has been recommended that intravenous (i.v.) K$_1$ be given empirically to exclude a contribution of vitamin K deficiency to the coagulopathy.
A commonly prescribed formulation of K<sub>1</sub> is Konakion® MM (F. Hoffmann-La Roche Ltd, Basle, Switzerland), which contains phylloquinone solubilised in glycocholate-phosphatidylcholine mixed micelles. We have shown that the mixed-micellar K<sub>1</sub> (MM K<sub>1</sub>) formulation is associated with a lower risk of anaphylactoid reactions after i.v. administration than the original Konakion, which contained the nonionic detergent Cremophor EL® as solubiliser<sup>10</sup>, but that<sup>10</sup> the intestinal absorption of MM K<sub>1</sub> in infants with conjugated hyperbilirubinaemia, given as prophylaxis against vitamin K deficiency bleeding of the newborn, is unreliable<sup>11-12</sup>. There is no information on the efficiency of intestinal absorption of MM K<sub>1</sub> in adults with liver disease.

The aims of this randomised, double-blind, placebo-controlled study were to: (i) assess the possible contribution of vitamin K deficiency to the coagulation disorder found in patients with severe acute liver damage, and (ii) compare the pharmacokinetics and efficacy of oral versus i.v. MM K<sub>1</sub> in correcting any underlying vitamin K deficiency.

**PATIENTS AND METHODS**

Over an eight-month period, 49 patients (24 women, 25 men; mean age 34 years, range 16-73 years) with, or at high risk of developing, ALF<sup>12-13</sup>, were transferred to the Liver Failure Unit of King’s College Hospital and enrolled into the study by one of two investigators (SPP and DR). As part of the eligibility criteria, all of the patients had an INR > 2 at admission, and none had received K<sub>1</sub> within the preceding three days. The commonest cause of acute liver dysfunction was acetaminophen (paracetamol) hepatotoxicity (n=37; 76%), followed by other drugs (ecstasy in four,
paroxetine in one) in 10%. The final diagnoses in the remainder were presumed nonA-E viral hepatitis of unknown origin in two, malignant hepatic liver infiltration in two, and one case each of acute fatty liver of pregnancy and *Amanita phalloides* poisoning.

At admission, 27 patients (55%) had already developed ALF and were encephalopathic and/or mechanically ventilated, and eight (16%) had a marked metabolic acidosis (arterial pH <7.3). All patients were managed according to a standard protocol for acute liver failure. Continuous veno-venous haemodiafiltration was instituted in anuric or oliguric patients with a serum creatinine level of > 400 µmol/l. Intravenous N-acetylcysteine and broad-spectrum antibiotics were administered routinely. Patients who developed grade III-IV encephalopathy were intubated and ventilated electively, and a nasogastric tube was inserted for enteral nutrition and drug administration.

The study medications (MM K₁ and placebo in identical-appearing ampoules) were paired and coded by the trial pharmacist, and stored at 4°C. The trial pharmacist also provided the random allocation sequence, in opaque consecutively numbered envelopes. On the day of admission, patients were randomised double-blind to: (i) placebo by mouth or nasogastric tube (made up to 10 ml in water) and 10 mg MM K₁ i.v. (given over 1 min), (ii) 10 mg MM K₁ by mouth/nasogastric tube and placebo i.v., or (iii) placebo/placebo. The study medications were administered by the patient’s nurse at 12:00 on the day of admission. The clinical status of the patients, and the results of standard biochemical and haematological tests, were assessed daily.
Assessment of vitamin K status

Vitamin K status was assessed from serum measurements of K\(_1\) and by a sensitive functional assay based on the detection of undercarboxylated species of prothrombin (PIVKA-II).

Blood samples were collected before administration of the study medications (baseline sample) and on the three consecutive mornings after admission, with further samples on days five and seven unless the patient had died or been discharged. At each sampling time, 10 ml of venous blood was collected into plain tubes, protected from light and allowed to clot at 4°C. Serum was separated by centrifugation and stored at -70°C.

Serum vitamin K\(_1\) assay: Serum K\(_1\) was measured by high performance liquid chromatography (HPLC) with electrochemical detection in the redox mode, as described previously \(^{14,15}\). Volumes of 0.05 ml serum were first analysed by a protocol designed to measure K\(_1\) concentrations in the pharmacological range (>5 ng/ml) \(^{14,15}\). If the level was <10 ng/ml by this protocol, volumes of 0.2-0.5 ml serum were subjected to a protocol for endogenous concentrations \(^{14,15}\). Menaquinone-6 was used as the internal standard. For 0.5 ml serum extracted, the lower limit of detection was 0.05 ng/ml. The mean intra- and inter-assay precision values (RSD %) were 3% and 9%, respectively, for concentrations in the pharmacological range, and 5% and 10% for endogenous concentrations. The normal adult reference range by the same assay was 0.17-0.68 ng/ml (median 0.37 ng/ml) in the fasting state, and 0.15-1.55 ng/ml (median 0.53 ng/ml) in non-fasting subjects \(^{15,16}\).
Serum PIVKA-II assay: Serum PIVKA-II was assayed using a conformation-specific monoclonal antibody (which does not cross-react with fully carboxylated native prothrombin) in a modification of a previously described ELISA-based assay 55. Serum PIVKA-II by immunoassay is conventionally expressed as Arbitrary Units per ml (AU/ml) since, in states of vitamin K deficiency, circulating PIVKA-II may comprise multiple forms of partially carboxylated prothrombin and neither their relative abundance in plasma nor their relative affinity for the antibody is known. Calibration is therefore made against PIVKA-II species purified from patients treated with oral anticoagulants. Using electrophoretic techniques, 1 AU is equivalent to 1 µg of purified PIVKA-II 55. The minimum limit of detection for our assay was 0.15 AU/ml. In 43 adult patients on warfarin therapy (INR > 1.5), the mean value in our laboratory was 40.0 AU/ml (range 6.9-99.5 AU/ml) 1617. As previously reported 1718, there was good agreement between the specificity of this assay and a commercial kit (Eitest mono-II; Eisai Co Ltd, Tokyo) which has been used widely for the detection of subclinical vitamin K deficiency 18-20-19-21.

Statistical analysis

Data are expressed as means ± SEM. Group means were compared using the the Student's t test (two-tailed), and differences in proportions were assessed using the $\chi^2$ test. Pearson’s correlation coefficients were calculated to assess the strength of relations between the serum $K_1$ terminal half-lives (determined by log-linear regression analysis of the 24 h and 48 h data) and the severity of liver and renal dysfunction.

Written, informed consent was obtained from the patients or their next-of-kin. The
study was approved by the Research Ethics Committee of King’s College Hospital.

**RESULTS**

The clinical details and laboratory values at admission of the three study groups are given in Table 1. The three groups were well-matched for sex, aetiology and severity of liver dysfunction, although patients in the oral group were somewhat younger than those in the other two groups (27 v 37 yr; p=0.03). The mean INR at admission was 6.4 (range 2.0 to 15), which fell improved progressively thereafter to 4.2 at 48 h and 1.6 at 96 h. The corresponding mean admission values for serum creatinine and bilirubin were 202 (49-700) mmol/l and 154 (6-916) mmol/l, respectively, which rose to peak values of 311 (45-752) mmol/l and 243 (16-886) mmol/l on day five of admission. A total of 32 patients (65%) developed ALF, either before their transfer to King’s (n=27) or during their subsequent admission (n=5).

Twenty-seven of the 49 patients (55%) made a full recovery with intensive care support, and eight others (16%) who fulfilled the King’s criteria for transplantation in ALF 1213 were transplanted on day 3-30 (median six) and later discharged. Fourteen other patients (29%) died 3-10 days (median six) after admission, generally due to chest sepsis with multiorgan failure or cerebral oedema. Ten patients in this group fulfilled transplant criteria, but either had medical or psychiatric contraindications to transplantation (n=7) or died before transplantation could be carried out (n=3).

Table 1:

**Clinical data and laboratory values at admission in the three study groups.**
Results are expressed as means with ranges.

<table>
<thead>
<tr>
<th></th>
<th>Vitamin K₁</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral</td>
<td>Intravenous</td>
</tr>
<tr>
<td>No.</td>
<td>15</td>
<td>16</td>
</tr>
<tr>
<td>Sex</td>
<td>8M, 7F</td>
<td>7M, 9F</td>
</tr>
<tr>
<td>Age (range)</td>
<td>27 (16-49)*†</td>
<td>37 (18-73)*</td>
</tr>
<tr>
<td>Cause of ALF: Acetaminophen_paracetamol Others</td>
<td>13 2</td>
<td>11 5 13 5</td>
</tr>
<tr>
<td>Serum bilirubin (normal, 3-20 µmol/l)</td>
<td>186 (21-916)</td>
<td>153 (6-483)</td>
</tr>
<tr>
<td>Aspartate aminotransferase (10-50 IU/l)</td>
<td>5839 (348-22000)</td>
<td>3199 (25-9369)</td>
</tr>
<tr>
<td>Alkaline phosphatase (30-150 IU/l)</td>
<td>122 (58-277)</td>
<td>208 (40-1665)</td>
</tr>
<tr>
<td>Gamma-glutamyl transferase (5-55 IU/l)</td>
<td>78 (31-190)</td>
<td>167 (18-1249)</td>
</tr>
<tr>
<td>International Normalised Ratio (0.7-1.2)</td>
<td>6.2 (2.8-12.1)</td>
<td>6.0 (2.0-15)</td>
</tr>
</tbody>
</table>

* p=0.03 oral v i.v. group. † p=0.03 oral v placebo group. There were no significant differences between the three groups with respect to the other variables.

**Serum vitamin K₁**

Mean baseline serum concentrations of K₁ were similar in the three groups, being 1.6 ±0.4 ng/ml (range, 0.2-6.5 ng/ml) in the i.v. MM K₁ group, 2.4±0.8 ng/ml (0.1-10.0 ng/ml) in those given MM K₁ orally, and 2.2±0.08 ng/ml (0.03-6.5 ng/ml) in the placebo group (NS). Three of the 49 patients (6%) had pretreatment serum K₁ levels below the normal limit of 0.15 ng/ml (one in the oral group and two in the placebo group), and a further two patients (both in the placebo group) developed low levels within 48 h after admission despite clinical improvement in both patients. In those given placebo, there was a progressive fall in mean serum K₁ concentrations with
time, from 2.2±0.08 ng/ml (0.03-6.5 ng/ml) at admission, to 1.8 ng/ml (0.1-4.5 ng/ml) at 48 h, 1.0 ng/ml (0.1-2.7 ng/ml) at five days, and to 0.7 ng/ml (0.5-1.3 ng/ml) on day seven.

Individual and mean serum concentrations of K₁ in the two supplemented groups, expressed on a logarithmic scale, are shown in Fig. 1. At 24 h after i.v. MM K₁, the peak serum K₁ concentrations was 91.5±39.2 ng/ml (range 7.2-650 ng/ml), compared with 17.2±8.4 ng/ml (range 0.3-91.8 ng/ml) after oral MM K₁ (p=0.08 i.v. v oral). When treatment failure was defined as an incremental K₁ rise < 10 ng/ml, one instance was recorded in the 16 patients (6%) given i.v. MM K₁, compared with 12 treatment failures in the 15 (80%) who received oral MM K₁ (p<0.0001).
Figure 1  Serum concentrations of vitamin K$_1$ after oral or i.v. mixed-micellar vitamin K$_1$. 
Serum PIVKA-II

At admission, nine of the 49 patients (18%) had mildly raised PIVKA-II concentrations of 0.15-0.91 AU/ml, consistent with subclinical vitamin K deficiency. These elevated levels fell by at least 50% within 48 h in two of the four patients given oral MM K₁, in both of the patients given i.v. MM K₁, and in none of the three in the placebo group (Fig. 2). In the two patients from the oral group whose serum PIVKA-II levels rose further after vitamin K, the maximum incremental K₁ rise of 2.3 ng/ml indicated poor intestinal absorption in both.

Two other patients had markedly raised PIVKA-II levels (> 10 AU/ml and 8 AU/ml), which were in the same range as that found in patients with overt vitamin K deficiency or during oral anticoagulation therapy. One of these patients was given i.v. K₁, and the PIVKA-II level fell from > 10 AU/ml to 3.3 AU/ml after 48 h (and to 0.50 AU/ml on day 7), with a corresponding fall improvement in the INR from 2.2 to 1.0. The other patient was in the placebo group, and the PIVKA-II level rose from 8 AU/ml to > 10 AU/ml at all subsequent time points between 24 h and 7 days. Following an initial fall improvement in the INR from 2.6 at admission to 1.3 at 48 h, the INR again increased to 2.6 on day 7 despite improving liver function tests, and subsequently returned to normal 48 h after the patient was removed from the trial and given i.v. MM K₁.
Figure 2  Serum concentrations of undercarboxylated prothrombin (PIVKA-II;
logarithmic scale) before and 48 h after mixed-micellar vitamin K$_1$ or placebo. The dashed horizontal line at 0.15 AU/ml represents the upper limit of normal.

**Vitamin K$_1$ pharmacokinetics**

In the 15 patients (12 in the i.v. group) with peak incremental serum K$_1$ levels > 10 ng/ml in whom half-lives could be determined, the mean serum terminal half-life of MM K$_1$ was 25.3±3.7 h (range, 6.6-55.9 h). Seventeen of the patients (35%) required renal support during their admission, with continuous veno-venous haemodiafiltration in 15 and haemodialysis in two. Amongst the patients requiring renal support, the mean serum K$_1$ half-life was 26.3±6.7 h, compared with a half-life of 24.7±4.6 h in those with preserved renal function (NS). There were no significant correlations between serum K$_1$ half-life and admission or peak serum creatinine concentrations, severity of liver disease (as assessed by the INR and serum bilirubin) or need for ventilation.

**DISCUSSION**

In severe acute liver disease, there are reductions in the plasma concentrations of several coagulation proteins, including the procoagulant vitamin K-dependent factors II, VII, IX and X and the anticoagulant protein C$^9$,$^{21,22}$ The hepatic synthesis of these vitamin K-dependent factors differs from other coagulation factors in that their functional activity is also dependent on the integrity of the microsomal $\gamma$-glutamyl carboxylation system, which converts the inactive protein precursors to their active
zymogens, with a Thus, reduced ratio of functional to antigenic levels of prothrombin being a hallmark of an impaired carboxylation resulting in the hepatic secretion of non-functional PIVKA-II. In ALF, it has been commonly assumed that the reduced levels of prothrombin (and other vitamin K-dependent proteins) are due to impaired hepatic protein synthesis. However, Kerr et al. showed recently that the factors that fall to the lowest levels in ALF are those which are directly activated after tissue factor generation — pointing to a tissue factor-initiated consumption of factors II, V, VII and X (but not factor IX) as a major cause of their depletion in ALF.

The present study has shown that over a quarter of patients with severe acute liver dysfunction have subclinical vitamin K deficiency at presentation which, if untreated, may progress to overt vitamin K deficiency with a raised INR and bleeding tendency. The PIVKA-II analyses showed that 11/49 patients (22%) presented with a functional defect of prothrombin γ-carboxylation. In most, PIVKA-II was mildly raised (0.15-1.0 AU/ml), consistent with subclinical vitamin K deficiency, but in two patients the PIVKA-II was in the range found in warfarin-anticoagulated patients (>7.0 AU/ml), indicating that a component of their raised INR was due to overt vitamin K deficiency. A smaller proportion of 3/49 patients (6%) had a low pre-treatment serum $\text{K}_1$ (<0.15 ng/ml), suggestive of a low tissue vitamin K status. As in previous reports, we did not detect an association between baseline serum $\text{K}_1$ and PIVKA-II levels. Serum $\text{K}_1$ concentrations at admission varied widely, presumably related in part to variations in dietary intake and inter-individual differences between circulating vitamin K and liver stores (which may include bacterial menaquinones; $\text{K}_2$ vitamins). Another possible reason for the lack of association between serum $\text{K}_1$ and PIVKA-II is that some patients may have received vitamin K more than three days before transfer to
King’s College Hospital. At admission, 10 (20%) had K₁ levels above the upper limit of the non-fasting range (1.6 ng/ml). PIVKA-II has a long terminal half-life and may remain detectable in plasma for several days after correction of vitamin K deficiency.

To the authors’ knowledge, this is the first detailed study of vitamin K status in severe acute liver dysfunction and the first placebo-controlled study of vitamin K prophylaxis using either the intravenous or oral route. Under normal physiological conditions, 40-70% of an oral dose of K₁ is absorbed from the jejunum and ileum of the upper intestine and as for other fat-soluble vitamins and highly lipid-soluble nutrients, the intraluminal phase of absorption involves the solubilisation of K₁ into mixed micelles. In the present study, we found that only 20% of patients given the oral MM formulation developed an incremental serum K₁ rise ≥ 10 ng/ml at 24 h, compared with all but one (94%) of those given i.v. K₁.

In the patients in whom serum half-lives could be estimated, the mean K₁ terminal half-life of 25.3 ± 3.7 h was about approximately twofold longer than that found in subjects with normal hepatic function given pharmacological doses of the same MM preparation. This finding of a prolonged terminal half-life in patients with severe acute liver dysfunction is not unexpected, since tracer experiments with labelled phylloquinone in normal individuals have shown that a sizable fraction of a single dose is rapidly catabolised in the liver, with at least 40-50% excreted in the faeces via the bile and 20% excreted in the urine within three days.

In summary, over a quarter of our patients presenting with severe acute liver damage had evidence of subclinical K₁ deficiency at admission, which was corrected by a
single dose of i.v. MM $K_1$. Intestinal absorption of MM $K_1$ in these patients was unreliable, so that there is no rationale to change our current practice of recommending i.v. $K_1$ to patients with severe liver disease and an associated coagulopathy. Based on the findings of a markedly prolonged serum $K_1$ half-life in these patients, a single dose of 10 mg $K_1$ given i.v. appears to be sufficient to maintain supraphysiological vitamin K blood levels for at least a week.

Acknowledgements

We thank Zahida Jabeen, Farhat Gilani and Julia Harvey for their excellent technical support. This work was supported by an unrestricted grant from F. Hoffmann-La Roche Ltd, Basel, Switzerland.

REFERENCES

10. Pereira SP, Williams R. Adverse events associated with vitamin $K_1$: results of a worldwide postmarketing surveillance programme. *Pharmacoepidemiol Drug*


